"Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis" 
NEJM Aug 22
http://www.nejm.org/doi/full/10.1056/NEJMoa1215734?query=featured_home 
"CONCLUSIONS

Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.)"